Shares of KemPharm Inc (NASDAQ:KMPH) have earned a consensus recommendation of “Buy” from the six brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $10.25.
KMPH has been the subject of several recent research reports. ValuEngine downgraded KemPharm from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Zacks Investment Research downgraded KemPharm from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. Royal Bank of Canada set a $9.00 price objective on KemPharm and gave the company a “buy” rating in a research note on Tuesday, January 16th. Oppenheimer set a $13.00 price objective on KemPharm and gave the company a “buy” rating in a research note on Sunday, February 25th. Finally, Canaccord Genuity set a $11.00 target price on shares of KemPharm and gave the company a “buy” rating in a research report on Friday, February 23rd.
KemPharm (NASDAQ:KMPH) traded up $0.50 during trading on Friday, hitting $7.00. The stock had a trading volume of 61,529 shares, compared to its average volume of 183,541. KemPharm has a one year low of $2.45 and a one year high of $7.45. The company has a debt-to-equity ratio of -1.92, a current ratio of 7.56 and a quick ratio of 7.56. The firm has a market capitalization of $99.67, a P/E ratio of -2.61 and a beta of 0.05.
A number of large investors have recently added to or reduced their stakes in KMPH. C WorldWide Group Holding A S increased its position in KemPharm by 14.1% during the 3rd quarter. C WorldWide Group Holding A S now owns 435,528 shares of the specialty pharmaceutical company’s stock valued at $1,611,000 after purchasing an additional 53,829 shares during the period. Victory Capital Management Inc. increased its position in KemPharm by 26.7% during the 4th quarter. Victory Capital Management Inc. now owns 162,077 shares of the specialty pharmaceutical company’s stock valued at $656,000 after purchasing an additional 34,114 shares during the period. Finally, Alyeska Investment Group L.P. increased its position in KemPharm by 1.8% during the 3rd quarter. Alyeska Investment Group L.P. now owns 992,338 shares of the specialty pharmaceutical company’s stock valued at $3,672,000 after purchasing an additional 17,721 shares during the period. 36.56% of the stock is owned by institutional investors and hedge funds.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.